Last reviewed · How we verify
14^C-labeled ertugliflozin for oral use
14^C-labeled ertugliflozin for oral use is a Small molecule drug developed by Merck Sharp & Dohme LLC. It is currently in Phase 1 development.
At a glance
| Generic name | 14^C-labeled ertugliflozin for oral use |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Headache
- Back Pain
- Nasal congestion
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 14^C-labeled ertugliflozin for oral use CI brief — competitive landscape report
- 14^C-labeled ertugliflozin for oral use updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI
Frequently asked questions about 14^C-labeled ertugliflozin for oral use
What is 14^C-labeled ertugliflozin for oral use?
14^C-labeled ertugliflozin for oral use is a Small molecule drug developed by Merck Sharp & Dohme LLC.
Who makes 14^C-labeled ertugliflozin for oral use?
14^C-labeled ertugliflozin for oral use is developed by Merck Sharp & Dohme LLC (see full Merck Sharp & Dohme LLC pipeline at /company/merck).
What development phase is 14^C-labeled ertugliflozin for oral use in?
14^C-labeled ertugliflozin for oral use is in Phase 1.
What are the side effects of 14^C-labeled ertugliflozin for oral use?
Common side effects of 14^C-labeled ertugliflozin for oral use include Headache, Back Pain, Nasal congestion.